文献速递乳腺癌放疗

新辅助化疗后腋窝淋巴结病理完全缓解的乳腺癌患者术后放疗:NSABP B-51研究的前奏

Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51?
PubMed 文献 · Radiother Oncol · 2021-06-29

该研究基于美国国家癌症数据库回顾性分析14,690例新辅助化疗后腋窝淋巴结病理完全缓解(ypN0)且接受乳房切除术的乳腺癌患者,比较术后放疗(PMRT)与未放疗的总生存(OS)。全组10年OS无显著差异(76.3% vs 78.6%,p=0.412);在NSABP B-51拟入组人群中(cT1-3 cN1)亦无显著差异(82.6% vs 80.0%,p=0.250)。PMRT可能对诊断时原发灶和/或淋巴结分期较晚(如cT3-4、cN3)但新辅助化疗后未进展的患者有益。

要点

  • 新辅助化疗后ypN0乳腺癌患者中,PMRT与未放疗的10年OS无显著差异。
  • 在NSABP B-51拟入组人群(cT1-3 cN1)中,PMRT未显著改善10年OS。
  • PMRT可能对cT3-4、cN3等较晚期但新辅助化疗后未进展的患者有益。

核心结论

  • 对于新辅助化疗后腋窝淋巴结病理完全缓解并接受乳房切除术的乳腺癌患者,全组及NSABP B-51拟入组人群中PMRT未显著改善10年OS。
  • PMRT可能对诊断时原发灶和/或淋巴结分期较晚(如cT3-4、cN3)但新辅助化疗后未进展的「中高危」患者有益。
  • 在NSABP B-51结果公布前,对于比其入组标准更晚期的患者,PMRT应继续作为标准治疗。

研究设计与样本

  • 回顾性队列研究,数据来源于美国国家癌症数据库(National Cancer Database)。
  • 纳入cT1-4N1-3M0乳腺癌接受新辅助化疗且乳房切除术后ypN0的女性,共14,690例。
  • 其中10,092例(69%)接受辅助PMRT,4,598例(31%)未接受。
  • 中位随访55.6个月,采用多因素logistic回归、Kaplan-Meier法、Cox比例风险模型及森林图分析。

主要发现

  • 全组10年OS:PMRT组76.3%,未放疗组78.6%(p=0.412)。
  • 在NSABP B-51拟入组人群(cT1-3 cN1)中,10年OS:PMRT组82.6%,未放疗组80.0%(p=0.250)。
  • PMRT对OS的影响随年龄或腋窝处理(清扫淋巴结数目)无显著差异。
  • PMRT使cT分期增加(如cT3-4)、ypT分期增加(ypT4可能因样本量小例外)及cN3患者获益(p<0.05)。

关键数值与推荐

  • 全组10年OS:PMRT组76.3% vs 未放疗组78.6%(p=0.412)。
  • NSABP B-51拟入组人群(cT1-3 cN1)10年OS:PMRT组82.6% vs 未放疗组80.0%(p=0.250)。
  • cT3-4、ypT分期增加(ypT4除外)及cN3患者接受PMRT的OS获益具有统计学意义(p<0.05)。

临床怎么用

  • 对于新辅助化疗后ypN0且接受乳房切除术的乳腺癌患者,全组水平PMRT未显著改善OS,需个体化决策。
  • 对于诊断时原发灶和/或淋巴结分期较晚(如cT3-4、cN3)但新辅助化疗后未进展的患者,PMRT可能带来OS获益。
  • NSABP B-51结果公布前,对于比其入组标准更晚期的患者,PMRT应继续作为标准治疗。

局限性

  • 回顾性研究,存在选择偏倚可能。
  • 无法排除组间无复发生存(RFS)的潜在差异,而RFS是NSABP B-51的主要终点。
  • 部分亚组(如ypT4)样本量小,结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The utility of post-mastectomy radiotherapy (PMRT) in women with a nodal complete response (CRn) to neoadjuvant chemotherapy (NAC) is unknown. The NSABP B-51 trial is evaluating this question, but has not reported results thus far. Therefore, we sought to answer this question with the National Cancer Database. METHODS: The National Cancer Database was queried for women with cT1-4N1-3M0 breast cancer who had undergone NAC and were ypN0 upon mastectomy. Statistics included multivariable logistic regression, Kaplan-Meier overall survival (OS) analysis, Cox proportional hazards modeling, and construction of forest plots. RESULTS: Of 14,690 women, 10,092 (69%) underwent adjuvant PMRT and 4598 (31%) did not. The median follow-up was 55.6 months. In all patients, the 10-year OS was 76.3% for PMRT and 78.6% without (p = 0.412). There were no notable effects of PMRT on OS based on age or the axillary management (number of nodes removed). Specifically, in the NSABP B-51 population of cT1-3 cN1 patients, the 10-year OS was 82.6% for PMRT and 80.0% without (p = 0.250). PMRT benefitted women with increasing cT stage (i.e. cT3-4), increasing ypT stages (with the exception of ypT4 potentially owing to small sample sizes), and cN3 cases (p < 0.05 for all). CONCLUSIONS: In the absence of published results from NSABP B-51, this assessment of over 14,000 women from a contemporary US database revealed that PMRT may be most useful for a "moderately-high" risk group - women with more advanced primary and/or nodal disease at diagnosis, yet with tumor biology favorable enough that the disease does not progress or remain stable after NAC. The OS findings notwithstanding, this study cannot exclude potential differences between groups in recurrence-free survival, which is the primary endpoint of NSABP B-51, While the results of the NSABP B-51 will confirm optimal management for patients with limited nodal disease having a CRn following NAC, the present results suggest PMRT should remain the standard of care for more advanced disease than NSABP B-51 eligibility criteria.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Haque W, Singh A, Verma V, et al. Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51? Radiother Oncol. 2021. PMID: 34214615. doi:10.1016/j.radonc.2021.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。